Virtu Financial LLC acquired a new position in shares of XBiotech Inc (NASDAQ:XBIT) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 15,682 shares of the biopharmaceutical company’s stock, valued at approximately $80,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XBIT. Millennium Management LLC purchased a new stake in XBiotech in the second quarter valued at $931,000. Vanguard Group Inc. raised its position in XBiotech by 5.5% in the third quarter. Vanguard Group Inc. now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after purchasing an additional 43,648 shares during the period. Finally, Vanguard Group Inc raised its position in XBiotech by 5.5% in the third quarter. Vanguard Group Inc now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after purchasing an additional 43,648 shares during the period. 4.29% of the stock is currently owned by institutional investors.
In other XBiotech news, Director W Thorpe Mckenzie bought 24,838 shares of XBiotech stock in a transaction on Monday, December 24th. The shares were bought at an average price of $5.88 per share, for a total transaction of $146,047.44. Following the completion of the transaction, the director now directly owns 3,398,600 shares of the company’s stock, valued at $19,983,768. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders acquired 31,338 shares of company stock worth $174,893 in the last 90 days. Company insiders own 37.00% of the company’s stock.
NASDAQ:XBIT opened at $8.42 on Wednesday. XBiotech Inc has a 52 week low of $2.13 and a 52 week high of $8.90.
Separately, ValuEngine upgraded XBiotech from a “hold” rating to a “buy” rating in a research report on Monday, January 7th.
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
See Also: Coverage Ratio
Want to see what other hedge funds are holding XBIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for XBiotech Inc (NASDAQ:XBIT).
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.